Himisha Beltran

Jan 7, 2025 | europeanurology.com | Himisha Beltran

This is written in loving memory of Dr. Felix Feng and in honor of his many accomplishments, leadership, and scientific contributions to the field of prostate cancer that will no doubt have long-lasting impact – shaping clinical care, translational research, and future generations of researchers. His achievements catapulted his career and that of many others, serving as a beacon of hope for countless patients and their families affected by prostate cancer.

Dec 13, 2024 | europeanurology.com | Rana R. McKay |Joshua Lang |Himisha Beltran

Platinum Priority – Editorial | Referring to the article published on pp.

Dec 11, 2024 | nature.com | Todd P. Knutson |Bin Luo |Michael Morris |Himisha Beltran |Emmanuel S. Antonarakis |Andrew Armstrong | +1 more

AbstractCirculating tumor DNA (ctDNA) in plasma cell free DNA (cfDNA) of cancer patients is associated with poor prognosis, but is challenging to detect from low plasma volumes. In metastatic castration-resistant prostate cancer (mCRPC), ctDNA assays are needed to prognosticate outcomes of patients treated with androgen receptor (AR) inhibitors.

Feb 11, 2024 | nature.com | Himisha Beltran |Michael Morris |Daniel George |Andrew Armstrong

AbstractCALGB 90401 (Alliance) was a phase III trial of 1050 patients with metastatic castration-resistant prostate cancer (mCRPC) comparing docetaxel, prednisone, bevacizumab (DP+B) versus DP alone. While this trial did not show an improvement in overall survival (OS), there were improved intermediate outcomes suggesting that subsets of men may derive benefit from this combination.

Dec 4, 2023 | nature.com | Himisha Beltran